Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis

BACKGROUND: Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5–6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations....

Descripción completa

Detalles Bibliográficos
Autores principales: Goulart, Bernardo HL, Clark, Jeffrey W, Lauwers, Gregory Y, Ryan, David P, Grenon, Nina, Muzikansky, Alona, Zhu, Andrew X
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663565/
https://www.ncbi.nlm.nih.gov/pubmed/19291303
http://dx.doi.org/10.1186/1756-8722-2-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663565/
https://www.ncbi.nlm.nih.gov/pubmed/19291303
http://dx.doi.org/10.1186/1756-8722-2-13

Ejemplares similares